Results 11 to 20 of about 593,464 (84)

Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study [PDF]

open access: yesDrug Design, Development and Therapy
Sandro Loche,1 Shankar Kanumakala,2 Philippe Backeljauw,3 Karl Otfried Schwab,4 Alfonso M Lechuga-Sancho,5– 7 Altaher Esmael,8 Dragan Urosevic,9 Anca Boldea,8 Markus Zabransky8 1Endocrinologia Pediatra e Centro, Screening Neonatale, Ospedale Pediatrico ...
Loche S   +8 more
doaj   +5 more sources

Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data. [PDF]

open access: yesEur J Pediatr, 2022
There are known geographical differences in growth hormone deficiency (GHD) patient populations and treatment practices. Here, we present a comparison of safety and effectiveness data from patients treated with recombinant human growth hormone (rhGH) in ...
Backeljauw P   +9 more
europepmc   +2 more sources

Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. [PDF]

open access: yesItal J Pediatr, 2016
Background: PATRO Children is an ongoing observational, longitudinal, non-interventional, global post-marketing surveillance study, which is investigating the long-term safety and effectiveness of Omnitrope®, a somatropin biosimilar to Genotropin®, in ...
Iughetti L   +17 more
europepmc   +2 more sources

Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. [PDF]

open access: yesJ Endocrinol Invest, 2017
To report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope(®), a somatropin biosimilar to Genotropin(®), in Italian patients with growth hormone deficiency (GHD) enrolled in the PATRO Adults ...
Ferone D   +11 more
europepmc   +3 more sources

Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults). [PDF]

open access: yesPituitary, 2021
To evaluate safety and effectiveness of biosimilar recombinant human growth hormone (rhGH; Omnitrope®) in adults with growth hormone deficiency (GHD), using data from the PATRO Adults study.PATRO Adults was a post-marketing surveillance study conducted ...
Höybye C   +8 more
europepmc   +2 more sources

A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial. [PDF]

open access: yesAdv Ther, 2015
An initial Phase III clinical trial has evaluated the efficacy and safety of biosimilar recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz) in Spanish children with growth hormone deficiency (GHD).
Borrás Pérez V   +13 more
europepmc   +2 more sources

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. [PDF]

open access: yesDrug Des Devel Ther, 2017
In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer).
López-Siguero JP   +5 more
europepmc   +2 more sources

Safety and Effectiveness of a Biosimilar Recombinant Growth Hormone in Adults with Growth Hormone Deficiency: Analysis of Final Data from PATRO Adults, an International Post-Marketing Surveillance Study [PDF]

open access: yesDrug Design, Development and Therapy
Paolo Beck-Peccoz,1 Charlotte Höybye,2 Suat Simsek,3 Günter Stalla,4 Robert  D Murray,5 Altaher Esmael,6 Dragan Urosevic,7 Anca Boldea,6 Markus Zabransky6 1Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore ...
Beck-Peccoz P   +8 more
doaj   +2 more sources

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data [PDF]

open access: yesDrug Design, Development and Therapy, 2017
Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Borrás Pérez MV   +5 more
doaj   +2 more sources

Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort [PDF]

open access: yes, 2020
Purpose: To investigate the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the somatropin biosimilar Omnitrope®. Methods: PATRO Children is an ongoing, multicenter, observational, post-marketing surveillance study. Children
Greggio N. A.   +57 more
core   +1 more source

Home - About - Disclaimer - Privacy